The pharmacokinetics (PK) of aprepitant are not affected in patients with end-stage renal disease (ESRD) or severe renal impairment

Author：  

Publisher： Adis International

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1494, 2005-01, pp. : 19-19

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

"Sitagliptin dose adjustments are recommended for patients with moderate or severe RI [renal insufficiency] or ESRD [end-stage renal disease]"

By  

Inpharma, Vol. 1, Iss. 1601, 2007-01 ,pp. : 18-18

Adis International

Access to resources Recommend Favorite

Pharmacokinetics of Rosiglitazone in Patients with End-stage Renal Disease

By Thompson-Culkin K   Zussman B   Miller AK   Freed MI  

The Journal of International Medical Research, Vol. 30, Iss. 4, 2002-07 ,pp. : 391-399

Field House Publishing

Access to resources Recommend Favorite

Among patients with end-stage renal disease (ESRD), there is considerable variation in Medicare spending

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 343, 2001-01 ,pp. : 6-6

Adis International

Access to resources Recommend Favorite

Pharmacokinetics and Blood Pressure Response of Losartan in End-Stage Renal Disease

By Sica D.A.  

Clinical Pharmacokinetics, Vol. 38, Iss. 6, 2000-06 ,pp. : 519-526

Adis International

Access to resources Recommend Favorite

Epidemiology of end-stage renal disease

By Roderick Paul  

Clinical Medicine, Vol. 2, Iss. 3, 2002-05 ,pp. : 200-204

Royal College Of Physicians

Access to resources Recommend Favorite